loading page

Remdesivir and COVID-19: Justified in Emergency Use Authorization?
  • Raiiq Ridwan
Raiiq Ridwan
Cambridge University Hospitals NHS Foundation Trust
Author Profile

Abstract

Since the advent of COVID-19 as a pandemic, multiple therapeutic options have been looked into as possible options for the management of COVID-19 disease. Remdesivir, a broad-spectrum anti-viral, has since been given Emergency Use Authorization by the US Food and Drug Agency (FDA). While cohort studies have shown benefit in the use of Remdesivir, the only Randomized Controlled Trial showed no statistically significant clinical benefit, and the other results from a trial by the NIH has only shown some benefit in reducing hospital admission in early results prior to peer review. In this scenario, with data lacking, is it justified for Remdesivir to be given Emergency Use Authorization?